Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740617 | 0.84 | MGAM (0.56) | LMNACNR2HTR3AHRH4MAPT | |
| SCHEMBL2157877 | 0.79 | BACE1 (0.39) | CNR2HTR3AHRH4MAPTBACE1 | |
| SCHEMBL2157873 | 0.79 | BACE1 (0.39) | CNR2HTR3AHRH4MAPTBACE1 | |
| SCHEMBL8007815 | 0.79 | NCK1 (0.55) | GRM2PTPN1BACE1PIM1 | |
| SCHEMBL31733680 | 0.79 | BACE1 (0.55) | GRM2PTPN1MAPTBACE1PIM1 | |
| SCHEMBL16093684 | 0.79 | BACE1 (0.55) | GRM2PTPN1BACE1PIM1HDAC1 | |
| SCHEMBL28071638 | 0.78 | RXFP1 (0.56) | CNR2KDM4E | |
| Hydrochloric Acid SCHEMBL31733671 | 0.77 | BACE1 (0.53) | GRM2PTPN1MAPTBACE1PIM1 | |
| SCHEMBL1668204 | 0.77 | TDP1 (0.46) | CNR2PTPN1MAPTPIM1KDM4E | |
| SCHEMBL4986476 | 0.76 | PIM1 (0.42) | GRM2LMNAPTPN1MAPTPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023231948-A1 | ISR INHIBITORS, METHOD FOR PREPARING SAME, AND USE THEREOF | 中国药科大学 | 2023-12-07 | — | — | WO | disclosed |
| CN-116768877-A | ISR inhibitor and preparation method and application thereof | 中国药科大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-104447540-A | Synthetic method of primary aryl amide compounds | UNIV HUNAN | 2015-03-25 | — | — | CN | disclosed |
| EP-2431370-B1 | Monoacylated 1,2-diaminocycloalkanes | DAIICHI SANKYO CO LTD (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20070112008-A1 | Saframycins, analogues and uses thereof | MYERS ANDREW G | 2007-05-17 | — | — | US | disclosed |
| US-7122549-B2 | Saframycins, analogues and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-10-17 | — | — | US | disclosed |
| US-6809099-B2 | FOR THERAPY OF CANCER | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-10-26 | — | — | US | disclosed |
| US-20040204419-A1 | Saframycins, analogues and uses thereof | MYERS ANDREW G (US) | 2004-10-14 | — | — | US | disclosed |
| EP-1339713-A2 | SAFRAMYCINS, ANALOGUES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030008873-A1 | Saframycins, analogues and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002040477-A2 | SAFRAMYCINS, ANALOGUES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204419-A1 | Saframycins, analogues and uses thereof | MYC, MAN1B1, MRPS18A | GRM2 4458/4885LMNA 1758/4885CNR2 2673/4885 |
| US-20070112008-A1 | Saframycins, analogues and uses thereof | MYC, MAN1B1, MRPS18A | GRM2 4510/4885LMNA 1818/4885CNR2 2627/4885 |
| US-20030008873-A1 | Saframycins, analogues and uses thereof | MYC, MAN1B1, MRPS18A | GRM2 4458/4885LMNA 1758/4885CNR2 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.